Semaglutide: 2-5-10mg*10 vials
$89.00 – $150.00Price range: $89.00 through $150.00
Semaglutide is a synthetic GLP-1 receptor agonist supplied in a convenient 10-vial research kit, with each vial containing 2mg, 5mg, or 10mg of lyophilized peptide. Widely utilized in laboratory studies, Semaglutide is researched for its role in glucose metabolism, appetite regulation, and cellular signaling pathways. Manufactured to high purity standards, each vial is designed to provide consistency and reliability for scientific research applications.
For research use only. Not intended for human consumption, medical use, or therapeutic purposes.
Buy Semaglutide Peptide Kit (10 Vials) | High-Purity GLP-1 Research Peptide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist extensively investigated in metabolic, endocrine, and gastrointestinal research. Through structural modifications that improve stability and prolong biological activity, Semaglutide has become one of the most extensively characterized peptide compounds in studies involving incretin biology, glucose regulation, and energy metabolism.
Available in 2 mg, 5 mg, and 10 mg strengths, this research-grade peptide undergoes rigorous analytical testing to ensure exceptional purity and consistency.
Product Highlights
- 10 vacuum-sealed lyophilized vials per kit
- Available in 2 mg, 5 mg, and 10 mg strengths
- ≥99% HPLC purity verified
- Mass spectrometry identity confirmation
- White lyophilized powder
- Certificate of Analysis (COA) available
- Excellent batch-to-batch consistency
- Intended exclusively for laboratory research
What Is Semaglutide?
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1). It was engineered to provide prolonged receptor activation through enhanced resistance to enzymatic degradation and increased albumin binding.
Its extended biological profile has made Semaglutide one of the most widely studied compounds in metabolic and endocrine investigations.
Discovery and Development
Semaglutide was developed by Novo Nordisk as a next-generation GLP-1 receptor agonist. Pharmaceutical formulations marketed under the brands Ozempic®, Wegovy®, and Rybelsus® have contributed to extensive scientific interest in incretin biology and metabolic signaling.
Since its introduction, Semaglutide has been investigated in numerous preclinical and clinical studies involving endocrine physiology and glucose homeostasis.
Structural Characteristics
Semaglutide contains amino acid substitutions and a C18 fatty diacid side chain that enhance albumin binding and increase resistance to enzymatic degradation. These modifications contribute to its prolonged biological activity compared with native GLP-1.
Mechanism of Action
Semaglutide functions as a selective GLP-1 receptor agonist. Researchers investigate its influence on:
- Glucose metabolism
- Insulin signaling pathways
- Appetite-associated mechanisms
- Gastric emptying
- Energy homeostasis
- Gastrointestinal physiology
- Endocrine communication networks
Primary Areas of Research
Metabolic Research
Experimental studies investigate interactions between GLP-1 receptor activation and glucose regulation.
Endocrine Function
Researchers examine the relationship between incretin signaling and hormonal communication pathways.
Appetite Signaling
Semaglutide has been extensively studied in models involving appetite-associated pathways and energy balance.
Gastrointestinal Physiology
Investigations continue into the effects of GLP-1 receptor activation on digestive system function and gastric motility.
Cardiometabolic Research
Scientists explore the relationship between incretin biology and cardiovascular physiology.
Semaglutide vs Tirzepatide
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Activity | GLP-1 | GLP-1 + GIP |
| Compound Type | Peptide | Dual Incretin Peptide |
| Biological Profile | Long Acting | Long Acting |
| Research Focus | Metabolic Signaling | Multi-Hormonal Signaling |
Semaglutide vs Liraglutide
| Feature | Semaglutide | Liraglutide |
|---|---|---|
| Duration | Long Acting | Daily Acting |
| Target | GLP-1 Receptor | GLP-1 Receptor |
| Research Focus | Metabolic Physiology | Metabolic Physiology |
Product Specifications
| Specification | Details |
|---|---|
| Compound | Semaglutide |
| Peptide Type | GLP-1 Receptor Agonist |
| CAS Number | 910463-68-2 |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4113.58 g/mol |
| Approximate Half-Life | About 1 Week |
| Purity | ≥99% HPLC Verified |
| Appearance | White Lyophilized Powder |
| Strengths Available | 2 mg, 5 mg, and 10 mg |
| Kit Size | 10 Vials |
| Intended Use | Laboratory Research Only |
Quality Assurance
Each production batch undergoes:
- HPLC purity analysis
- Mass spectrometry identity confirmation
- Batch traceability verification
- Quality control inspection
- Certificate of Analysis documentation
Storage Guidelines
For optimal stability:
- Store at 2–8°C.
- Protect from heat and moisture.
- Avoid repeated freeze-thaw cycles.
- Keep containers sealed until use.
Frequently Asked Questions
What is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist widely investigated in metabolic and endocrine research.
Is Semaglutide a peptide?
Yes. Semaglutide is a synthetic peptide analog of glucagon-like peptide-1.
Who developed Semaglutide?
Semaglutide was developed by Novo Nordisk as a next-generation GLP-1 receptor agonist.
What receptor does Semaglutide target?
Semaglutide selectively activates the GLP-1 receptor.
What is the half-life of Semaglutide?
Semaglutide possesses an approximate half-life of one week, contributing to its prolonged biological activity.
What is the difference between Semaglutide and Tirzepatide?
Semaglutide primarily targets GLP-1 receptors, while Tirzepatide activates both GLP-1 and GIP receptors.
What brands contain Semaglutide?
Semaglutide is marketed in pharmaceutical formulations under the brand names Ozempic®, Wegovy®, and Rybelsus®.
What are the most popular Semaglutide products available in the United States?
The most recognized Semaglutide products available in the United States are Ozempic®, Wegovy®, and Rybelsus®, all developed by Novo Nordisk. Although each formulation contains Semaglutide as the active ingredient, they differ in dosage forms and approved indications. These products have contributed significantly to scientific interest in GLP-1 receptor biology and metabolic regulation.
Is a Certificate of Analysis available?
Yes. Certificates of Analysis are available to verify purity and identity.
Related Research Compounds
- Tirzepatide
- Retatrutide
- Cagrilintide
- Liraglutide
- Tesofensine
- AOD-9604
Scientific References
- Lau J, Bloch P, Schäffer L, et al.
- Knudsen LB, Lau J.
- Wilding JPH, Batterham RL, Calanna S, et al.
- STEP clinical trial program.
- SUSTAIN clinical trial program.
- PIONEER clinical trial program.
Conclusion
Semaglutide represents a major advancement in GLP-1 receptor agonist research. Its prolonged half-life, enhanced molecular stability, and extensive scientific investigation have established it as one of the most important peptide compounds for studying incretin biology, endocrine signaling, and metabolic physiology.
Research Use Only
Semaglutide is supplied exclusively for laboratory research purposes. It is not intended for human or veterinary use and is not approved to diagnose, treat, cure, or prevent any disease.
Scientific Resources
For more detailed scientific information, you can visit the PubChem entry for Semaglutide.
Related Research Peptides
| Size |
10mg*10 vials ,5mg*10 vials ,2mg*10 vials |
|---|
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.

Reviews
There are no reviews yet.